Literature DB >> 29427591

Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation.

Sofia Christakoudi1, Manohursingh Runglall2, Paula Mobillo3, Irene Rebollo-Mesa4, Tjir-Li Tsui5, Estefania Nova-Lamperti3, Sonia Norris3, Yogesh Kamra3, Rachel Hilton6, Sunil Bhandari7, Richard Baker8, David Berglund9, Sue Carr10, David Game6, Sian Griffin11, Philip A Kalra12, Robert Lewis13, Patrick B Mark14, Stephen D Marks15, Iain Macphee16, William McKane17, Markus G Mohaupt18, Ravi Pararajasingam19, Sui Phin Kon20, Daniel Serón21, Manish Sinha22, Beatriz Tucker20, Ondrej Viklický23, Robert I Lechler24, Graham M Lord25, Daniel Stahl26, Maria P Hernandez-Fuentes24.   

Abstract

Steroid conversion (HSD11B1, HSD11B2, H6PD) and receptor genes (NR3C1, NR3C2) were examined in kidney-transplant recipients with "operational tolerance" and chronic rejection (CR), independently and within the context of 88 tolerance-associated genes. Associations with cellular types were explored. Peripheral whole-blood gene-expression levels (RT-qPCR-based) and cell counts were adjusted for immunosuppressant drug intake. Tolerant (n = 17), stable (n = 190) and CR patients (n = 37) were compared. Healthy controls (n = 14) were used as reference. The anti-inflammatory glucocorticoid receptor (NR3C1) and the cortisol-activating HSD11B1 and H6PD genes were up-regulated in CR and were lowest in tolerant patients. The pro-inflammatory mineralocorticoid gene (NR3C2) was downregulated in stable and CR patients. NR3C1 was associated with neutrophils and NR3C2 with T-cells. Steroid conversion and receptor genes, alone, enabled classification of tolerant patients and were major contributors to gene-expression signatures of both, tolerance and CR, alongside known tolerance-associated genes, revealing a key role of steroid regulation and response in kidney transplantation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic rejection; Kidney; Steroid conversion; Steroid receptor genes; Tolerance; Transplantation

Mesh:

Substances:

Year:  2018        PMID: 29427591     DOI: 10.1016/j.mce.2018.01.021

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

1.  Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy.

Authors:  Sofia Christakoudi; Manohursingh Runglall; Paula Mobillo; Irene Rebollo-Mesa; Tjir-Li Tsui; Estefania Nova-Lamperti; Catharine Taube; Sonia Norris; Yogesh Kamra; Rachel Hilton; Titus Augustine; Sunil Bhandari; Richard Baker; David Berglund; Sue Carr; David Game; Sian Griffin; Philip A Kalra; Robert Lewis; Patrick B Mark; Stephen D Marks; Iain MacPhee; William McKane; Markus G Mohaupt; Estela Paz-Artal; Sui Phin Kon; Daniel Serón; Manish D Sinha; Beatriz Tucker; Ondrej Viklický; Daniel Stahl; Robert I Lechler; Graham M Lord; Maria P Hernandez-Fuentes
Journal:  EBioMedicine       Date:  2020-07-21       Impact factor: 8.143

2.  Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study.

Authors:  Laura Llinàs-Mallol; Dolores Redondo-Pachón; María José Pérez-Sáez; Dàlia Raïch-Regué; Marisa Mir; José Yélamos; Miguel López-Botet; Julio Pascual; Marta Crespo
Journal:  Sci Rep       Date:  2019-05-15       Impact factor: 4.379

3.  Identifying Synergistic Mechanisms of Multiple Ingredients in Shuangbai Tablets against Proteinuria by Virtual Screening and a Network Pharmacology Approach.

Authors:  Xiaoqin Ma; Meixiang Yu; Chenxia Hao; Wanhua Yang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-06       Impact factor: 2.629

4.  Comprehensive Metabolomics and Network Pharmacology to Explore the Mechanism of 5-Hydroxymethyl Furfural in the Treatment of Blood Deficiency Syndrome.

Authors:  Wensen Zhang; Na Cui; Fazhi Su; Yangyang Wang; Bingyou Yang; Yanping Sun; Wei Guan; Haixue Kuang; Qiuhong Wang
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.